Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis

Journal of Surgical Oncology

Volumn 106, Issue 1, 2012, Pages 84-88

  Song, Tae Jin ^a,b   Fong, Yuman ^a   Cho, Sung Jin ^b   Gönen, Mithat ^a   Hezel, Michael ^a   Tuorto, Scott ^a   Choi, Sang Yong ^b   Kim, Young Chul ^b   Suh, Sung Ock ^b   Koo, Bum Hwan ^b   Chae, Yang Seok ^b   Jarnagin, William R ^a   Klimstra, David S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Korea University College of Medicine   (South Korea)

Author keywords

HepPar1; Immunohistochemistry; Molecular characterization; South Korean

Indexed keywords

ANTIBODY; CYCLIN D1; KI 67 ANTIGEN; PARAFFIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; ASIAN; ASIAN AMERICAN; CANCER CENTER; CANCER PATIENT; CANCER SURGERY; CELL CYCLE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TISSUE SECTION; VIRUS HEPATITIS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PARAFFIN; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; REPUBLIC OF KOREA; RISK FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 84862807841     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23036     Document Type: Article

References (38)

1. Okuda K: Hepatocellular carcinoma. J Hepatol 2000;32:225-237.
2. Staib F, Hussain SP, Hofseth LJ, et al.: Tp53 and liver carcinogenesis. Hum Mutat 2003;21:201-216. (Pubitemid 36292963)
3. Wang XW, Hussain SP, Huo TI, et al.: Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002;181-182:43-47. (Pubitemid 36015671)
4. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-S66.
5. Pisani P, Bray F, Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
6. El Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
7. Department of Health and Human Services, Centers for Disease Control and Prevention, National Cancer Institutes. U.S. Cancer Statistics Working Group; United States Cancer Statistics: 2000 Incidence. Atlanta, GA. 50-77. 2003.
8. American Cancer Society. Cancer facts and figures 2007. Atlanta, GA: American Cancer Society; 2007.
9. Cancer Registration and Biostatistics Branch and National Cancer Center. Cancer Statistics in Korea 2000. http://wwwicanregorkr/Upload-Data/etc-data/ 1038475918 doc. 2004. [Cited 2006 Jun 9].
10. Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: A global overview. Clin Liver Dis 2010;14:1-21, vii.
11. Suh DJ, Jeong SH: Current status of hepatitis C virus infection in Korea. Intervirology 2006;49:70-75.
12. Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: Cancer implications. Nat Rev Cancer 2009;9:95-107.
13. Wade M, Wahl GM: Targeting Mdm2 and Mdmx in cancer therapy: Better living through medicinal chemistry? Mol Cancer Res 2009;7:1-11.
14. Hoos A, Cordon-Cardo C: Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations. Lab Invest 2001;81:1331-1338. (Pubitemid 32980155)
15. Hoos A, Urist MJ, Stojadinovic A, et al.: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-1251. (Pubitemid 32281288)
16. Kononen J, Bubendorf L, Kallioniemi A, et al.: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847. (Pubitemid 28331029)
17. Camp RL, Charette LA, Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949. (Pubitemid 32012762)
18. Packeisen J, Buerger H, Krech R, et al.: Tissue microarrays: A new approach for quality control in immunohistochemistry. J Clin Pathol 2002;55:613-615.
19. el Deiry WS: Regulation of p53 downstream genes. Sem Cancer Biol 1998;8:345-357.
20. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327. (Pubitemid 23317333)
21. Offner S, Schmaus W, Witter K, et al.: p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci USA 1999;96:6942-6946. (Pubitemid 29274989)
22. Zhang MF, Zhang ZY, Fu J, et al.: Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med 2009;7:110.
23. Hollstein M, Sidransky D, Vogelstein B, et al.: p53 mutations in human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
24. Ding X, Park YN, Taltavull TC, et al.: Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: Comparison among six different countries. Jpn J Infect Dis 2003;56:12-18. (Pubitemid 36626515)
25. Hosono S, Chou MJ, Lee CS, et al.: Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene 1993;8:491-496. (Pubitemid 23073766)
26. Hsu HC, Tseng HJ, Lai PL, et al.: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness. Cancer Res 1993;53:4691-4694.
27. Yoon YJ, Chang HY, Ahn SH, et al.: MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008;29:1192-1196. (Pubitemid 351964880)
28. Oda T, Tsuda H, Scarpa A, et al.: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52:6358-6364.
29. Reeves ME, DeMatteo RP: Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 2000;19:84-93.
30. Teramoto T, Satonaka K, Kitazawa S, et al.: p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 1994;54:231-235.
31. Yang JM, Wang RQ, Bu BG, et al.: Effect of HCV infection on expression of several cancer-associated gene products in hepatocellular carcinoma. World J Gastroenterol 1999;5:25-27.
32. Piette J, Neel H, Marechal V: MDM2: Keeping p53 under control. Oncogene 1997;15:1001-1010. (Pubitemid 27401954)
33. Friedman SL, Shaulian E, Littlewood T, et al.: Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene 1997;15:63-70. (Pubitemid 27348097)
34. Momand J, Jung D, Wilczynski S, et al.: The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-3459. (Pubitemid 28347214)
35. Jones SN, Hancock AR, Vogel H, et al.: Overexpression of MDM2 in mice reveals a p53-independent role for MDM2 in tumorigenesis. Proc Natl Acad Sci USA 1998;95:15608-15612. (Pubitemid 29018747)
36. Jablkowski M, Bocian A, Bialkowska J, et al.: A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. J Exp Clin Cancer Res 2005;24:117-125. (Pubitemid 40655872)
37. Schoniger-Hekele M, Hanel S, Wrba F, et al.: Hepatocellular carcinoma - Survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 2005;25:62-69. (Pubitemid 40298246)
38. Endo K, Ueda T, Ohta T, et al.: Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000;20:209-215. (Pubitemid 30342718)